BACKGROUND AND OBJECTIVES:Eptifibatide is indicated during percutaneous coronary intervention (PCI) with continuation for 18-24 hours post procedure but is associated with bleeding. We examined the efficacy and safety of shorter post-PCI eptifibatide infusions in high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients. METHODS: EARLY ACS patients treated with PCI and eptifibatide were grouped by post-procedure infusion duration: <10, 10-13, 13-17, and 17-25 (per protocol) hours. Adjusted estimated event rates for 96-hour death/myocardial infarction (MI)/recurrent ischaemia requiring urgent revascularization (RIUR), 30-day death/MI, post-PCI packed red blood cell (PRBC) transfusion, and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) moderate/severe bleeding were obtained using inverse-propensity weighting to account for informative censoring of infusions. RESULTS: Among 3271 eptifibatide-treated PCI patients, there were 66 96-hour death/MI/RIUR events, 94 30-day death/MI events, 127 PRBC transfusions, and 115 GUSTO moderate/severe bleeds. Compared with per protocol, patients receiving post-PCI infusions <10 hours had similar adjusted estimated rates of 96-hour death/MI/RIUR (absolute difference 0.021 higher; 0.040 vs. 0.019, 95% CI -0.023 to 0.064; p=0.35) and 30-day death/MI (0.020 higher; 0.046 vs. 0.026, 95% CI -0.021 to 0.062; p=0.34). There were also no differences in ischaemic outcomes between infusions of 10-17 hours and per-protocol infusions. Adjusted estimated rates of PRBC transfusion were higher for the <10-hour infusion group compared with per protocol (0.048 higher; 0.079 vs. 0.031, 95% CI 0.005 to 0.091, p=0.03) but were similar for other groups. Adjusted GUSTO moderate/severe bleeding rates were similar to per-protocol rates for all groups. CONCLUSIONS: In high-risk NSTE ACS patients, post-PCI eptifibatide infusions <18 hours were not associated with worse ischaemic outcomes. Shorter eptifibatide infusions in this population may be feasible.
RCT Entities:
BACKGROUND AND OBJECTIVES:Eptifibatide is indicated during percutaneous coronary intervention (PCI) with continuation for 18-24 hours post procedure but is associated with bleeding. We examined the efficacy and safety of shorter post-PCI eptifibatide infusions in high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients. METHODS: EARLY ACSpatients treated with PCI and eptifibatide were grouped by post-procedure infusion duration: <10, 10-13, 13-17, and 17-25 (per protocol) hours. Adjusted estimated event rates for 96-hour death/myocardial infarction (MI)/recurrent ischaemia requiring urgent revascularization (RIUR), 30-day death/MI, post-PCI packed red blood cell (PRBC) transfusion, and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) moderate/severe bleeding were obtained using inverse-propensity weighting to account for informative censoring of infusions. RESULTS: Among 3271 eptifibatide-treated PCI patients, there were 66 96-hour death/MI/RIUR events, 94 30-day death/MI events, 127 PRBC transfusions, and 115 GUSTO moderate/severe bleeds. Compared with per protocol, patients receiving post-PCI infusions <10 hours had similar adjusted estimated rates of 96-hour death/MI/RIUR (absolute difference 0.021 higher; 0.040 vs. 0.019, 95% CI -0.023 to 0.064; p=0.35) and 30-day death/MI (0.020 higher; 0.046 vs. 0.026, 95% CI -0.021 to 0.062; p=0.34). There were also no differences in ischaemic outcomes between infusions of 10-17 hours and per-protocol infusions. Adjusted estimated rates of PRBC transfusion were higher for the <10-hour infusion group compared with per protocol (0.048 higher; 0.079 vs. 0.031, 95% CI 0.005 to 0.091, p=0.03) but were similar for other groups. Adjusted GUSTO moderate/severe bleeding rates were similar to per-protocol rates for all groups. CONCLUSIONS: In high-risk NSTE ACSpatients, post-PCI eptifibatide infusions <18 hours were not associated with worse ischaemic outcomes. Shorter eptifibatide infusions in this population may be feasible.
Authors: R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette K Wenger; R Scott Wright Journal: J Am Coll Cardiol Date: 2011-03-28 Impact factor: 24.094
Authors: Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger Journal: Eur Heart J Date: 2011-08-26 Impact factor: 29.983
Authors: J C O'Shea; G E Hafley; S Greenberg; V Hasselblad; T J Lorenz; M M Kitt; J Strony; J E Tcheng Journal: JAMA Date: 2001-05-16 Impact factor: 56.272
Authors: Eric Boersma; Robert A Harrington; David J Moliterno; Harvey White; Pierre Théroux; Frans Van de Werf; Anneke de Torbal; Paul W Armstrong; Lars C Wallentin; Robert G Wilcox; John Simes; Robert M Califf; Eric J Topol; Maarten L Simoons Journal: Lancet Date: 2002-01-19 Impact factor: 79.321
Authors: Mitul B Kadakia; Nihar R Desai; Karen P Alexander; Anita Y Chen; Joanne M Foody; Christopher P Cannon; Stephen D Wiviott; Benjamin M Scirica Journal: JACC Cardiovasc Interv Date: 2010-11 Impact factor: 11.195
Authors: Annapoorna S Kini; Victor H T Chen; Prakash Krishnan; Paul Lee; Michael C Kim; Angelica Mares; Javed Suleman; Pedro R Moreno; Samin K Sharma Journal: Am Heart J Date: 2008-07-02 Impact factor: 4.749
Authors: Anthony Y Fung; Jacqueline Saw; Andrew Starovoytov; Cameron Densem; Percy Jokhi; Simon J Walsh; Rebecca S Fox; Karin H Humphries; Eve Aymong; Donald R Ricci; John G Webb; Jaap N Hamburger; Ronald G Carere; Christopher E Buller Journal: J Am Coll Cardiol Date: 2009-03-10 Impact factor: 24.094
Authors: Robert P Giugliano; Jennifer A White; Christoph Bode; Paul W Armstrong; Gilles Montalescot; Basil S Lewis; Arnoud van 't Hof; Lisa G Berdan; Kerry L Lee; John T Strony; Steven Hildemann; Enrico Veltri; Frans Van de Werf; Eugene Braunwald; Robert A Harrington; Robert M Califf; L Kristin Newby Journal: N Engl J Med Date: 2009-03-30 Impact factor: 91.245
Authors: Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-02-28